{"id":"NCT01020019","sponsor":"New York State Psychiatric Institute","briefTitle":"Combined Pharmacotherapy for Cannabis Dependency","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-01","primaryCompletion":"2014-09","completion":"2014-09","firstPosted":"2009-11-25","resultsPosted":"2016-05-11","lastUpdate":"2019-04-24"},"enrollment":156,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cannabis Dependence","Marijuana Dependence"],"interventions":[{"type":"DRUG","name":"Dronabinol","otherNames":["Marinol"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Lofexidine","otherNames":[]}],"arms":[{"label":"Lofexidine and Dronabinol","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to see if Lofexidine in combination with Marinol is superior to placebo in achieving abstinence, reducing cannabis use and reducing withdrawal in cannabis-dependent patients seeking treatment for their marijuana use.","primaryOutcome":{"measure":"21 Days of Consecutive Abstinence as Measured by the Time-line Followback.","timeFrame":"reported daily for 12 weeks/ or study participation","effectByArm":[{"arm":"Placebo","deltaMin":18,"sd":null},{"arm":"Lofexidine and Dronabinol","deltaMin":17,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["29457671"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":61},"commonTop":["fatigue","dry mouth","dizzy","insomnia","headache"]}}